Dube Eric M 4

What Happened
Eric M. Dube, CEO of Travere Therapeutics (TVTX), reported sales and awards. On Feb 3, 2026 he sold 66,452 shares at $32.06 ($2,130,451) and 33,635 shares at $32.70 ($1,099,865) — a total of 100,087 shares for roughly $3.23 million. On Jan 31, 2026 he was granted restricted stock units (RSUs): 113,800 RSUs and 303,600 RSUs (the latter reported as a derivative award). The RSU grants show an acquisition price of $0.00 (typical for awards).

Key Details

• Transaction dates: RSU grants dated 2026-01-31; sales executed 2026-02-03.
• Sales breakdown: 66,452 shares @ $32.06 = $2,130,451 (weighted avg $32.06; range $31.52–$32.52); 33,635 shares @ $32.70 = $1,099,865 (weighted avg $32.70; range $32.5248–$32.88). Total proceeds ≈ $3,230,316.
• Grants: 113,800 RSUs + 303,600 RSUs = 417,400 RSUs (each RSU = right to one share on vesting).
• Footnotes: Sales were made under a written 10b5-1 trading plan adopted June 16, 2025; the sale included shares sold to cover tax withholding on RSU vesting. Standard option vesting schedule referenced (1/4 at first anniversary, then monthly over 36 months).
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: No late-filing flag indicated in the provided data.

Context
The sales were executed under a pre-established 10b5-1 plan and included shares to cover taxes on vested RSUs, which is a common, routine reason for insider stock sales. This filing reports both awards (RSUs) and routine disposals; purchases would generally be considered a stronger bullish signal than routine sales.